Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baxdrostat - CinCor Pharma

Next Previous
Drug Profile

Baxdrostat - CinCor Pharma

Alternative Names: CIN-107

Latest Information Update: 05 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer AstraZeneca; CinCor Pharma; CinRx Pharma
  • Class Amides; Antihypertensives; Antisecretories; Isoquinolines; Small molecules
  • Mechanism of Action Cytochrome P-450 CYP11B2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperaldosteronism; Hypertension; Renal failure
  • No development reported Spinal cord disorders

Most Recent Events

  • 30 Oct 2025 AstraZeneca plans a phase II BaxDuo-Baltic trial for Hypertension and Kidney disorders (Combination therapy) in Argentina, Bulgaria, Canada, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, USA (PO, Tablets) (NCT07222917)
  • 08 Oct 2025 Efficacy and adverse events data from a phase III trial in Hypertension released by AstraZeneca
  • 30 Aug 2025 Efficacy and adverse events data from phase III trial in Hypertension releases by AstraZeneca

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top